695
Views
5
CrossRef citations to date
0
Altmetric
Review

Recent progress in small molecule TBK1 inhibitors: a patent review (2015– 2020)

& ORCID Icon
Pages 785-794 | Received 23 Nov 2020, Accepted 15 Mar 2021, Published online: 31 Mar 2021

References

  • Yin M, Wang X, Lu J. Advances in IKBKE as a potential target for cancer therapy. Can Med.. 2020;9(1):247–258.
  • Verhelst K, Verstrepen L, Carpentier I, et al. IkB kinase ε (IKK): a therapeutic target in inflammation and cancer. Biocem Pharmacol.. 2013;85(7):873–880.
  • Ramadass V, Vaiyapuri T, Tergaonkar V. Small molecule NF-κB pathway inhibitors in clinic. Int J Mol Sci. 2020;21(14):5164.
  • Thomson DW, Poeckel D, Zinn N, et al. Discovery of GSK8612, a highly selective and potent TBK1 inhibitor. ACS Med Chem Lett. 2019;10(5):780–785.
  • Hasan M, Yan N. Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies. Pharmacol Res. 2016;111:336–342. .
  • Zhao C, Zhao W. TANK-binding kinase 1 as a novel therapeutic target for viral diseases. Expert Opin Ther Targets. 2019;23(5):437–446. .
  • Tanaka Y, Chen ZJ. STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. 2012;214:ra20. Sci. Signaling.
  • Louis C, Burns C, Wicks I. TANK-binding kinase 1- dependent responses in health and autoimmunity. Front Immunol. 2018;9:434.
  • Ullah MO, Sweet MJ, Mansell A, et al. TRIF Dependent TLR signaling, Its functions in host defense and inflammation, and its potential as a therapeutic target. J. Leukocyte Biol.. 2016;100(1):27–45.
  • Longhi MP, Trumpfheller C, Idoyaga J, et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with Poly IC as Adjuvant. J Exp Med. 2009;206(7):1589–1602.
  • Muskardin TLW, Niewold TB. Type I interferon in rheumatic diseases. Nat Rev Rheumatol. 2018;14(4):214–228.
  • Jin J, Xiao Y, Chang J-H, et al. The kinase TBK1 controls IgA class switching by negatively regulating noncanonical NF-ΚB signaling. Nat Immunol. 2012;13(11):1101–1109.
  • Marchlik E, Thakker P, Carlson T, et al. Tbk1 activity exhibit immune cell infiltrates in multiple tissues and increased susceptibility to LPS-induced lethality. J. Leukocyte Biol.. 2010;88(6):1171–1180.
  • Cruz VH, Brekken RA. Assessment of TANK-binding kinase 1 as a therapeutic target in cancer. J. Cell Commum. Signal. 2018;12(1): 83–90. .
  • Ramanjulu JM, Pesiridis GS, Yang J, et al. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature 2018;564(7736):439–443.
  • Chiang S-H, Bazuine M, Lumeng CN, et al. The protein kinase ikkepsilon regulates energy balance in obese mice. Cell 2009;138(5):961–975.
  • Zhao P, Wong KI, Sun X, et al. TBK1 at the crossroads of inflammation and energy homeostasis in adipose tissue. Cell. 2018;172(4):731–743.
  • Reilly SM, Chiang S-H, Decker SJ, et al. An inhibitor of the protein kinases TBK1 and IKK-ε improves obesity-related metabolic dysfunctions in mice. Nat Med. 2013;19(3):313–321.
  • Makino H, Saijo T, Ashida Y, et al. Mechanism of action of an antiallergic agent, amlexanox (AA-673), in inhibiting histamine release from mast cells. Acceleration of cAMP generation and inhibition of phosphodiesterase. International Archives of Allergy and Applied Immunology. 1987;82(1):66–71.
  • Bell J. Amlexanox for the treatment of recurrent aphthous ulcers. Clinical drug investigation.. 2005;25(9):555–566.
  • Cirulli ET, Lasseigne BN, Petrovski S, et al.,, . Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science. 2015;347(6229):1436–1441.
  • Freischmidt A, Wieland T, Richter B, et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat Neurosci. 2015;18(5):631–636.
  • Majo M, Topp SD, Smith BN, et al. ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase function. Neurobiol Aging. 2018;71:266.e1-266.e10.
  • Gerbino V, Kaunga E, Ye J, et al. The loss of TBK1 kinase activity in motor neurons or in all cell types differentially impacts ALS disease progression in SOD1 mice. Neuron 2020;106(5):789–805.
  • Oakes JA, Davies MC, Collins MO. TBK1: a new player in ALS linking autophagy and neuroinflammation. Mol Brain. 2017;10(1):5. .
  • Pilli M, Arko-Mensah J, Ponpuak M, et al. TBK-1 promotes autophagy-mediated antimicrobial defense by controlling autophagosome maturation. Immunity 2010;37(2):223–234.
  • Clark K, Plater L, Peggie M, et al. Use of pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IκB Kinase ε: a distinct upstream kinase mediates Ser-172 phosphorylation and activation. J Biol Chem. 2009;284(21):14136–14146.
  • Bain J, Plater L, Elliott M, et al. The selectivity of protein kinases inhibitors: a further update. Biochem J. 2007;408(3):297–315.
  • Clark K, Peggie M, Plater L, et al. Novel cross-talk within the IKK family controls innate immunity. Biochem J. 2011;434(1):93–104.
  • Clark K, Takeuchi O, Akira S, et al. The TRAF-associated protein TANK facilitates cross-talk within IkappaB kinase family during toll-like receptor signaling. Proc Natl Acad Sci USA. 2011;108(41):17093–17098.
  • Yu T, Yang Y, Yin DQ, et al. TBK1 Inhibitors: a review of patent literature (2011– 2014). Expert Opin Ther Pat. 2015;25(12):1385–1396.
  • The General Hospital Corporation. Methods relating to DNA-sensing pathway related conditions. US20150202223 (2015).
  • The General Hospital Corporation. Targeting innate immune signaling in neuroinflammation and neurodegeneration. WO2017173451 (2017).
  • The Regents of the University of Michigan. Combinations of IKKe/TBK1 Inhibitors with beta adrenergic agonists or sympathetic nervous system activators. WO2015119624 (2015).
  • The Regents of the University of California. Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition. US20160015709 (2016).
  • Dana-Farber Cancer Institute Inc. Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy. WO2019014663 (2019).
  • Dana-Farber Cancer Institute Inc. Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways. WO2018226685 (2018).
  • CAMP4 Therapeutics Corporation. Methods and compositions for treating urea cycle disorders, in particular OTC deficiency. WO2019071276 (2019).
  • Rosa Karl. Transfection method comprising nonviral gene delivery systems. US20190264228 (2019).
  • Rosa Karl. Transfection method comprising nonviral gene delivery systems. WO2018019341 (2018).
  • Precision Biosciences Inc. Methods for reducing DNA-induced cytotoxicity and enhancing gene editing in primary cells. WO2018201144 (2018).
  • Domainex. Pyrimidine compounds as inhibitors of protein kinases IKK epsilon and/or TBK1, Processes for their Preparation, and pharmaceutical compositions containing them. WO010826; (2012).
  • Domainex Limited. 5-(Pyrimidin-4-yl)-2-(pyrrolidin-1-yl)nicotinonitrile Compounds as IKKE, TBK1 and/or SIK2 Kinases inhibitors. WO2018154315 (2018).
  • Merck Patent GmbH. Thiazole derivatives. US9249114 (2016).
  • Merck Patent GmbH. Pyrimidine TBK/IKKε Inhibitor compounds and uses thereof. WO2019079375 (2019).
  • Merck Patent GmbH. Pyrimidine TBK/IKKε inhibitor compounds and uses thereof. WO2019079373 (2019).
  • Merck Patent GmbH. TBK/IKK inhibitor compounds and uses thereof. US20160376283 (2016).
  • Gilead Sciences. Tank-binding kinase inhibitor compounds. US2015344473 (2015).
  • Gilead Sciences. Aminotriazine derivatives useful as TANK-binding kinase inhibitor compounds. WO2016049211 (2016).
  • Gilead Sciences. Tank-binding kinase inhibitor compounds. WO2017106556 (2017).
  • Takeda Pharmaceutical Company. Heteroarylamide Inhibitors of TBK1. WO2015134171 (2015).
  • Takeda Pharmaceutical Company. Heteroarylamide Inhibitors of TBK1. WO2016057338 (2016).
  • Heymann F, Hamesch K, Weiskirchen R, et al. The concanavalin a model of acute hepatitis in mice. Lab Anim-UK.. 2015;49(1_suppl):12–20.
  • Green Cross Corporation. Pyrazole derivatives as TNIK, IKKe and TBK1 inhibitors and pharmaceutical composition comprising same. US20160289196 (2016).
  • Green Cross Corporation. 7-Azaindole or 4,7-diazaindole derivatives as IKK epsilon and TBK1 inhibitor and pharmaceutical composition comprising same. US20160297815 (2016).
  • Green Cross Corporation. Compounds as TNIK, IKK epsilon and TBK1 inhibitors and pharmaceutical composition comprising same. US20160311772 (2016).
  • Yamada T, Masuda M. Emergence of TNIK inhibitors in cancer therapeutics. Cancer Sci. 2017;108(5):818–823.
  • Bayer Pharma. Substituted heteroarylbenzimidazole compounds. WO2017207534 (2017).
  • Bayer Pharma. Substituted heteroarylbenzimidazole compounds. WO2017102091 (2017).
  • Lefranc J, Schulze VK, Hillig RC, et al. Discovery of BAY-985, a highly selective TBK1/IKKε inhibitor. J Med Chem. 2020;63(2):601–612. .
  • GlaxoSmithKline. TBK1 inhibitor compounds. WO2019233891 (2019).
  • Toure M, Crews CM. Small molecule PROTACs: new approaches to protein degradation. Angew Chem Int Ed. 2016;55(6):1966–1973.
  • Arvinas Inc. Tank-binding Kinase-1 protacs and associated methods of use. WO2016197114 (2016).
  • Arvinas Inc. Cereblon Ligands and Bifunctional Compounds Comprising the Same. US20180215731 (2018).
  • Arvinas Inc. Imide-based modulators of proteolysis and associated methods of use. US20160058872 (2016).
  • Arvinas Inc. Imide-based modulators of proteolysis and associated methods of use. US20150291562 (2016).
  • Crew AP, Raina K, Dong H, et al. Identification and characterization of von Hippel-Lindau-recruiting proteolysis targeting chimeras (PROTACs) of TANK-binding kinase 1. J Med Chem. 2018;61(2):583–598. .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.